Wedbush Raises Solventum (NYSE:SOLV) Price Target to $101.00

Solventum (NYSE:SOLV) had its price objective raised by equities researchers at Wedbush from $94.00 to $101.00 in a research note issued on Thursday,Benzinga reports. The firm presently has an “outperform” rating on the stock. Wedbush’s target price indicates a potential upside of 19.53% from the company’s current price.

Several other research analysts also recently weighed in on SOLV. BMO Capital Markets assumed coverage on shares of Solventum in a research report on Wednesday, July 8th. They issued a “market perform” rating and a $81.00 target price on the stock. UBS Group reiterated a “buy” rating and set a $101.00 price objective on shares of Solventum in a research report on Thursday. KeyCorp increased their price objective on Solventum from $93.00 to $102.00 and gave the stock an “overweight” rating in a report on Thursday. Wells Fargo & Company cut their price objective on shares of Solventum from $83.00 to $70.00 and set an “equal weight” rating on the stock in a report on Wednesday, May 6th. Finally, BTIG Research boosted their target price on shares of Solventum from $91.00 to $95.00 and gave the stock a “buy” rating in a report on Thursday. Seven analysts have rated the stock with a Buy rating, five have assigned a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat, the company has a consensus rating of “Hold” and an average target price of $90.45.

Solventum Stock Performance

Shares of NYSE SOLV traded down $2.98 during trading on Thursday, reaching $84.50. 645,530 shares of the company traded hands, compared to its average volume of 1,407,590. The stock has a market capitalization of $14.63 billion, a PE ratio of 10.36, a P/E/G ratio of 1.36 and a beta of 0.60. Solventum has a 52-week low of $62.38 and a 52-week high of $90.00. The company has a quick ratio of 0.75, a current ratio of 1.07 and a debt-to-equity ratio of 0.96. The firm has a 50 day simple moving average of $79.09 and a 200-day simple moving average of $74.36.

Solventum (NYSE:SOLV) last announced its quarterly earnings data on Wednesday, August 5th. The company reported $2.55 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.91 by $0.64. Solventum had a return on equity of 23.51% and a net margin of 17.33%.The firm had revenue of $2.21 billion during the quarter, compared to analysts’ expectations of $2.15 billion. During the same period last year, the business posted $1.69 earnings per share. The company’s revenue for the quarter was up 2.2% compared to the same quarter last year. Solventum has set its FY 2026 guidance at 7.100-7.200 EPS. Equities research analysts anticipate that Solventum will post 6.58 earnings per share for the current year.

Institutional Investors Weigh In On Solventum

Several hedge funds have recently added to or reduced their stakes in the business. Stoneridge Investment Partners LLC bought a new position in shares of Solventum in the second quarter worth $689,000. Leverty Financial Group LLC boosted its position in Solventum by 5.4% during the second quarter. Leverty Financial Group LLC now owns 5,318 shares of the company’s stock valued at $410,000 after purchasing an additional 274 shares in the last quarter. Fruth Investment Management increased its holdings in shares of Solventum by 8.2% during the 2nd quarter. Fruth Investment Management now owns 3,649 shares of the company’s stock valued at $281,000 after purchasing an additional 275 shares in the last quarter. Handelsbanken Fonder AB grew its holdings in Solventum by 11.8% in the 2nd quarter. Handelsbanken Fonder AB now owns 52,900 shares of the company’s stock valued at $4,081,000 after buying an additional 5,600 shares in the last quarter. Finally, First Bank & Trust increased its holdings in Solventum by 9.7% during the 2nd quarter. First Bank & Trust now owns 5,741 shares of the company’s stock worth $443,000 after purchasing an additional 509 shares during the period.

More Solventum News

Here are the key news stories impacting Solventum this week:

• Positive Sentiment: Quarterly earnings and revenue exceeded expectations. Solventum reported second-quarter adjusted EPS of $2.55, well above the $1.91 consensus and up from $1.69 a year earlier. Revenue reached $2.21 billion versus estimates of $2.15 billion, while organic sales increased 9.5%. Solventum Reports Second Quarter 2026 Financial Results
• Positive Sentiment: Management raised its 2026 outlook. Solventum increased full-year adjusted EPS guidance to $7.10-$7.20, above the approximately $6.55 analyst consensus, and also raised its expectations for organic sales growth and free cash flow. Solventum Raises 2026 EPS Guidance
• Positive Sentiment: Analyst sentiment improved. Stifel Nicolaus raised its price target from $90 to $100 and upgraded Solventum to “buy,” implying approximately 18.9% potential upside from the cited price. This supports the view that the earnings beat and higher guidance could improve the company’s valuation. Benzinga Analyst Update
• Neutral Sentiment: Solventum plans to separate its Health Information Systems business. The company says the move will create a more focused MedTech company, allow the healthcare software business to pursue its own growth strategy and potentially unlock shareholder value. However, the separation will require execution and could create near-term uncertainty, particularly amid activist pressure to divest the business. Solventum to Separate Healthcare Software Business

Solventum Company Profile

Solventum Corporation, a healthcare company, engages in the developing, manufacturing, and commercializing a portfolio of solutions to address critical customer and patient needs. It operates through four segments: Medsurg, Dental Solutions, Health Information Systems, and Purification and Filtration. The Medsurg segment is a provider of solutions including advanced wound care, I.V. site management, sterilization assurance, temperature management, surgical supplies, stethoscopes, and medical electrodes.